Key facts
- Notable investors include iAccel (Seongnam-si).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Cellshine
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellshine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellshine
Developer of ophthalmic diagnostic devices designed to enable precise detection and analysis of ocular conditions. The company develops goblet cell imaging technology, non-contact ocular imaging devices, fluorescent staining agents, and AI-based image analysis tools that quantify goblet cells and generate diagnostic reports, enabling clinicians to evaluate eye conditions such as dry eye disease with improved diagnostic accuracy.
- Sector
- Healthcare
- HQ
- Gwacheon-si, South Korea
- Founded
- 2024
- Website
- cellshine.co.kr/
- Ownership
- Privately Held (backing)
Cellshine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellshine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellshine in its N-PORT filings yet. We sweep new filings monthly.